Which Frontline EGFR TKI Should be Used in NSCLC?
Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.
Clinical Pearls
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.
- Patients with EGFR-mutated NSCLC should preferentially receive an EGFR TKI, not chemotherapy.
- It is still unknown which EGFR TKI should be administered first.
- A trial is underway comparing gefitinib with afatinib in the frontline setting.
Recent Videos
Related Content
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
February 17th 2025Article
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.
Read More
